The causal relationship between antihypertensive drugs and knee osteoarthritis: A drug target Mendelian randomization study.

Knee osteoarthritis (KOA) is a painful joint condition that affects millions of people worldwide, and research has shown that people with high blood pressure are more likely to develop it as well. Scientists wanted to understand whether blood pressure medications might also influence the risk of developing knee osteoarthritis — and if so, which ones could be most helpful.

In this study, researchers used a powerful genetic analysis technique called Mendelian randomization, which uses DNA variations to help establish cause-and-effect relationships between factors like medications and diseases. By analyzing large genetic datasets, they looked at how different blood pressure drug targets affected the likelihood of developing knee osteoarthritis.

The most important discovery was that lower activity of a gene called SLC12A2 was linked to a meaningfully reduced risk of knee osteoarthritis. Drugs that inhibit the SLC12A2 protein — a type of blood pressure medication — appeared to offer a protective benefit for knee joints. This suggests that for patients managing both high blood pressure and knee osteoarthritis, choosing an SLC12A2-inhibiting medication could potentially address both conditions at once.

For people living with knee osteoarthritis, this research adds to a growing body of evidence that the condition has complex, systemic roots — not just wear and tear on the joints. Managing cardiovascular health may play a meaningful role in protecting joint health over time.

Acupuncture is widely used as a complementary approach for knee osteoarthritis, helping to reduce pain, decrease inflammation, and improve mobility without the side effects of medications. When combined with appropriate medical care, acupuncture may support a more holistic management plan for people dealing with both hypertension and knee pain. To explore this approach, seek out a licensed and qualified acupuncture practitioner in your area.

This drug-target Mendelian randomization (MR) study investigated the causal relationship between antihypertensive medications and knee osteoarthritis (KOA), leveraging genome-wide association study (GWAS) data and SNPs near drug-target genes as instrumental variables for systolic blood pressure. Among the antihypertensive drug targets analyzed, reduced expression of SLC12A2 — the gene encoding the NKCC1 cotransporter, targeted by certain diuretics — demonstrated a statistically significant association with decreased KOA risk (OR: 0.915, 95% CI: 0.869–0.964, P < .001). No specific sample size was reported in the abstract, though GWAS-scale datasets were utilized. The study did not involve a clinical trial population. Key clinical takeaway: In patients presenting with comorbid hypertension and KOA, SLC12A2 inhibitors may offer dual therapeutic benefit, warranting consideration in prescribing decisions. For acupuncture practitioners, this highlights the systemic inflammatory and vascular mechanisms underlying KOA, reinforcing the value of integrative care strategies targeting both cardiovascular and musculoskeletal pathways.